CEO defends $300,000-per-year cost for a drug for a rare form of muscular dystrophy
Sarepta's Doug Ingram responds to a question about the high cost for a drug for Duchenne muscular dystrophy.
Sarepta's Doug Ingram responds to a question about the high cost for a drug for Duchenne muscular dystrophy.